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ABSTRACT: The differentiation of osteoblasts from mesenchymal precur-
sors requires a series of cell fate decisions controlled by a hierarchy of
transcription factors. Among these are RUNX2, Osterix (OSX), ATF4,
and a large number of nuclear coregulators. During bone development,
initial RUNX2 expression coincides with the formation of mesenchymal
condensations well before the branching of chondrogenic and osteogenic
lineages. Given that RUNX2 is expressed so early and participates in
several stages of bone formation, it is not surprising that it is subject
to a variety of controls. These include regulation by nuclear accessory
factors and posttranslational modification, especially phosphorylation.
Specific examples of RUNX2 regulation include interactions with DLX
proteins and ATF4 and phosphorylation by the ERK/MAP kinase path-
way. RUNX2 is regulated via phosphorylation of critical serine residues in
the P/S/T domain. MAPK activation of RUNX2 was also found to occur in
vivo. Transgenic expression of constitutively active MEK1 in osteoblasts
accelerated skeletal development while a dominant-negative MEK1 re-
tarded development in a RUNX2-dependent manner. These studies allow
us to begin understanding the complex mechanisms necessary to fine-
tune bone formation in response to extracellular stimuli including ECM
interactions, mechanical loads, and hormonal stimulation.
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Osteoblast and chondrocyte differentiation is controlled by a hierarchy of
transcription factors that are expressed in a defined temporal sequence
(FIG. 1). RUNX2, an essential factor for bone and hypertrophic cartilage forma-
tion, is expressed very early in skeletal development, first appearing with the
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FIGURE 1. Transcription factor control of skeletal lineages. Major transcription fac-
tors that, based on genetic studies, are involved in osteoblast and chondrocyte differentiation
are included in this chart. Also shown is the sequential nature of transcription factor expres-
sion with RUNX2 persisting throughout osteoblast and chondrocyte lineages (see text).
formation of mesenchymal condensations in areas destined to become bone
and persisting through subsequent stages of bone formation.1 Several other
transcription factors function together with RUNX2 to move cells down chon-
drocyte or osteoblast lineages. For osteoblasts, this is accomplished by Osterix
(Osx), which commits osteochondroprogenitor cells to the osteoblast lineage.2
Subsequently, another factor, ATF4, controls the transcriptional activity of
mature osteoblasts.3 RUNX2 also participates in the chondrogenic lineage.
However, at early stages, it is likely suppressed by the chondrocyte-specific
factors, Sox 8/9.4 However, Sox factors are downregulated to permit RUNX2
to coordinate chondrocyte hypertrophy. Evidence for this model largely comes
from genetic studies showing bone phenotypes of increasing severity as Runx2,
Osx, or Atf4 are knocked out. Thus, skeletal development in Runx2-deficient
embryos fails to progress beyond the cartilage anlage stage.5,6 Fetuses, which
die at birth of respiratory failure, have no detectable mineral in either bones or
cartilage. In contrast, Osx -/- embryos have hypertrophic cartilage and normal
levels of RUNX2, suggesting that this factor is downstream of RUNX2.2 ATF4
-/- mice have a milder phenotype consistent with this factor having a regulatory
function in bone formation.3
An interesting feature of this scheme is that most of the known RUNX2 tar-
get genes are only expressed at specific stages of chondrogenic or osteogenic
lineages, yet RUNX2 is present throughout both lineages. RUNX2 mRNA is
first expressed at E9.5, peaks at E12.5 well before any mineralization has oc-
curred, and continues to be present through the later stages of development.1
This essentially constitutive expression of RUNX2 once skeletal development
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FIGURE 2. RUNX2 protein levels are not well correlated with transcriptional activity.
MC3T3-E1 clone 4 preosteoblast cells were grown in control (–) or ascorbate-containing
medium (+). At the times indicated, RUNX2 protein levels were determined by Western
blotting (A) while Runx2 (Osf2), Ocn and Bsp mRNA levels (B–D) were measured on
Northern blots (B) and quantified by densitometry. (C) Runx2; (D) Ocn and Bsp. Legend:
open symbols = control; closed symbols = ascorbate. For panel D, Ocn mRNA (m, l), Bsp
mRNA (o, n). From Xiao et al. 1998.7
has commenced implies that other factors or signals must be regulating its
activity. FIGURE 2 shows an example of how other factors can regulate RUNX2
activity. In this experiment, MC3T3-E1 preosteoblast cells were induced to
differentiate by growth in ascorbic acid, thereby allowing cells to secrete
a collagenous ECM. Over time, as ECM accumulates, there is a dramatic
induction of osteoblast marker genes, such as bone sialoprotein and osteocalcin,
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FIGURE 3. In vivo binding of RUNX2 and DLX5 to chromatin sites in differenti-
ated and undifferentiated cells. (A) Schematic of the proximal Bsp promoter. RUNX2 and
homeodomain (DLX5) protein-binding sites are indicated. (B) Comparison of Bsp chro-
matin occupancy by RUNX2 and DLX5. Chromatin immunoprecipitation (ChIP) assays
were used to detect RUNX2 and DLX5 bound to the proximal Bsp promoter in control
(–AA) and differentiated (+AA) MC3T3-E1 clone 4 cells. Antibodies used for ChIP are
indicated. Note that RUNX2 remains chromatin associated regardless of differentiated state
while Dl×5 is only present in differentiated cells. From Roca et al., 2005.8
but RUNX2 mRNA and protein levels only increase 1.5- to 2-fold. Similarly,
the amount of RUNX2 bound to the promoter of target genes as measured
by chromatin immunoprecipitation also remains relatively unchanged during
differentiation.7 FIGURE 3 shows RUNX2 bound to the proximal Bsp promoter.
We identified two RUNX2 sites and a DLX5 homeodomain protein-binding
site in this region and showed that these sites cooperate to control expres-
sion in osteoblasts.8 Surprisingly, when RUNX2 chromatin occupancy was
compared in control versus differentiated osteoblasts, no obvious differences
were observed. In contrast, DLX5 chromatin occupancy was only observed in
differentiated cells. However, total DLX5 protein measured by Western blot
was equivalent in control and differentiated cells indicating that the affinity of
DLX5 for chromatin (and possibly Runx2) increases with differentiation.
There are at least two possible ways RUNX2 transcriptional activity could
be regulated in the absence of changes in RUNX2 protein levels. First, as
suggested by the DLX5 result discussed above, levels of cofactors or ability
of cofactors to interact with RUNX2 could be regulated. Second, covalent
modification could alter RUNX2 transcriptional activity.
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The first possibility is probably a very common control mechanism espe-
cially when we consider the broad range of factors known to interact with
RUNX2. For example, CBF forms heterodimers with all members of the
Runx family.9 RUNX2 also interacts with ATF4 and this factor may mediate
some of the responses of osteoblasts to PTH.10,11 SMAD proteins, media-
tors of BMP/TGF actions, can also stimulate RUNX2 activity.12 In addition,
there are a number of inhibitory factors. SOX9, mentioned above, suppresses
RUNX2-dependent chondrocyte hypertrophy.4 TWIST may prevent RUNX2
stimulation of mineralization in developing cranial bones to prevent craniosyn-
ostosis.13 Last, histone deacetylases (HDACs) and HDAC accessory factors,
such as mSin3a, are known to bind RUNX2 and keep chromatin in a deacety-
lated, inactive state.14
Posttranslational modification represents the second major mechanism for
controlling RUNX2 activity. Over the past decade, we described a pathway
involving integrin-mediated activation of the ERK/MAP kinase pathway that
results in phosphorylation and stimulation of RUNX2 transcriptional activity.
Integrins provide information to cells about the ECM environment and me-
diate cell attachment and spreading.15 Integrins are also major mediators of
mechanical loads experienced by cells and may transduce information about
ECM stiffness to control differentiation.16,17 In addition to providing conti-
nuity between the ECM and the actin-containing cytoskeleton, integrins are
important signal transduction molecules that activate Ras-ERK and p38 MAP
kinase pathways, calcium channels, and mechanosensors.15
Osteoblast differentiation requires elaboration of a collagenous ECM. This
explains the well-known requirement for ascorbic acid in osteoblast differ-
entiation since this vitamin cofactor is essential for secretion of the collage-
nous ECM.18 An example of ECM-mediated osteoblast differentiation was
shown in FIGURE 2. Bone sialoprotein and osteocalcin, two osteoblast mark-
ers, are only expressed in cells grown in ascorbate-containing medium. In
studies that will not be extensively discussed in this article, we showed that
the response of osteoblasts to ECM is mediated by 21 integrins and the
ERK/MAP kinase pathway.7,19,20 We specifically showed that osteoblast dif-
ferentiation could be blocked with specific inhibitors of collagen synthesis
and integrin-collagen binding. Furthermore, inhibition of MAPK signaling
using either pharmacological inhibitors or dominant-negative pathway inter-
mediates blocked differentiation. In contrast, induction of osteoblast gene
expression was induced with a constitutively active MAPK intermediate,
MEK1.
Initially, studies with the osteocalcin gene were used to relate MAPK re-
sponsiveness to RUNX2. We found that MAPK activation via transfection of
cells with constitutively active MEK1 (MEK-SP) could induce the RUNX2-
responsive Ocn gene while dominant-negative MEK1 (MEK-DN) was in-
hibitory.20 An examination of the Ocn promoter for MAPK-responsive se-
quence elements identified two RUNX2-binding sites called OSE2a and b.
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FIGURE 4. RUNX2 phosphorylation. (A) Cartoon showing major domains of RUNX2
and their known functions. (B) RUNX2 phosphorylation increases with osteoblast differen-
tiation. MC3T3-E1 clone 4 cells were grown in control or differentiation (AA-containing)
medium for 8 days before metabolic labeling with [32P] orthophosphate. RUNX2 was im-
munoprecipitated from nuclear extracts and visualized by autoradiography. Total RUNX2
was measured by Western blotting with RUNX2-specific antibody. (C) ERK/MAPK in-
creases phosphorylation in the RUNX2 P/S/T domain. COS7 cells were transfected with
RUNX2 and constitutively active MEK1 (MEK(SP)) expression vectors as indicated.
RUNX2 phosphorylation was measured as in panel B. Phosphorylation of a truncated
RUNX2 lacking the entire PST domain (PST) is also shown (bottom). Note lack of
MEK(SP)-dependent phosphorylation. From Franceschi et al., 2003.28
Mutation of either of these sites reduced MAPK responsiveness with the
proximal site, OSE2a, having the strongest effect on Ocn promoter activity.21
As might be expected, activation of MAPK, either by ascorbate addition or
transfection of cells with MEK-SP results in increased RUNX2 phosphoryla-
tion (FIG. 4 and Ref. 20). Examination of different truncations of the RUNX2
protein showed that the C-terminal proline/serine/threonine region (P/S/T do-
main) of RUNX2 was required for both MAPK responsiveness and phos-
phorylation (FIG. 4 and Ref. 20). More detailed deletional analysis further
localized a minimal region for MAPK responsiveness between amino acids
254 and 320 (result not shown). The specific identification and functional sig-
nificance of ERK/MAPK phosphorylation sites in RUNX2 will be reported
separately.
A number of other stimuli that act through the ERK/MAPK pathway have
been shown to stimulate RUNX2 phosphorylation and transcriptional activity.
For example, we showed that FGF2 via its receptor, FGFR2, can rapidly stim-
ulate ERK1/2 and RUNX2 phosphorylation and Ocn gene expression.22 A
related study showed that PKC, a second kinase activated by the FGFR2,
202 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
is also required for Ocn stimulation and that this kinase uses a distinct
site in RUNX2 (S247) that can be resolved from ERK/MAPK sites.23 Last,
exposure of osteoblasts to mechanical loading was shown to stimulate RUNX2
phosphorylation and osteoblast gene expression.24–26
All the studies discussed above were conducted in cell culture. To establish
the importance of the ERK/MAPK pathway and RUNX2 phosphorylation to
osteoblast function in vivo, we took a transgenic approach.27 Transgenes were
constructed using a 0.6 kb mOG2 promoter to specifically drive MEK-SP
and MEK-DN expression in osteoblasts. Transgene expression was detected
only in bones and had a time course of expression during development that
parallels expression of the endogenous Ocn gene. Examination of ERK1/2
phosphorylation in calvarial osteoblasts derived from these animals showed
a 50% increase in cells from Mek-sp mice and a 50% decrease in Mek-dn
cells (see Ref. 27). This indicates that transgene expression leads to subtle
changes in MAPK activity that resemble fluctuations normally induced by
physiological stimuli. Examination of skeletal whole mounts of transgenic
mice revealed that Mek-dn decreased skeletal size and calvarial mineralization
while these parameters were increased in Mek-sp mice (FIG. 5A–F). Histology
of long bones revealed an additional interesting difference between wild-type
and transgenic mice (FIG. 5G). At E15.5, long bones are normally undergoing
endochondral ossification in diaphyseal regions. However, in Mek-dn mice,
this process is drastically delayed with only early bony collar formation be-
ing visible. In contrast, in the Mek-sp mice, endochondral bone formation is
accelerated.
We next examined if transgenic modification of osteoblast MAPK activ-
ity could alter RUNX2 phosphorylation and transcriptional activity (FIG. 6).
For this experiment, we isolated calvarial osteoblasts from transgenic mice and
conducted metabolic labeling with [32P] orthophosphate followed by immuno-
precipitation. Cells were also transfected with a Runx2 reporter gene to mea-
sure transcriptional activity. Clearly, RUNX2 phosphorylation was increased
in Mek-sp cells as was luciferase activity of the Ocn reporter gene. Also, as
expected, Mek-sp stimulated in vitro osteoblast differentiation as measured by
induction of osteoblast marker mRNAs or mineralization while differentiation
was inhibited in Mek-sp cells (see Ref. 27).
To provide evidence that MAPK effects on skeletal development are me-
diated by RUNX2, we took a genetic approach. Runx2 +/− mice are known
to have a characteristic phenotype (hypoplastic clavicles, patent fontanelles)
that is a phenocopy of the human genetic disease, cleidocranial dysplasia or
CCD.5 We reason that if MAPK acts by altering RUNX2 activity, calvaria and
clavicles should be selectively sensitive to the Mek transgene when RUNX2 is
limiting (i.e., in Runx2 +/− mice). To test this, Runx2 +/− mice were crossed
with Mek-sp or Mek-dn transgenic lines and the resulting skeletal phenotypes
were examined at E19 (FIG. 7). Note the reduced calvarial mineralization and
tiny clavicles in the Runx2 +/− embryos. The presence of the Mek-sp trans-
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FIGURE 5. Altered skeletal development in TgMek-dn and TgMek-sp mice. (A) Whole
mounts of E15.5 skeletons stained with alcian blue and alizarin red. (D) Effects of transgene
expression on embryo weights. (B, E) Cranial bones showing differences in mineralization
(B) and quantification of mineralized area (expressed as percent of total calvarial area,
E). (C, F) Hindlimbs showing differences in the size of bones with transgene expression
(C) and quantification of femur lengths (F). (G) Histology of long bones from wild-type,
TgMek-dn and TgMek-sp mice. Note delay in bony collar and trabecular bone in TgMek-dn
embryos. Bar = 250 m. Statistical analysis values are expressed as means ± SD, n =
8/group. ∗ significantly different from wild-type at P < 0.01. From Ge et al., 2007.27
gene led to a clear rescue of the CCD phenotype with increased clavicle size
and calvarial mineralization. In the presence of Mek-dn, effects on Runx2 +/−
mice were even more dramatic. In this case, the Mek-dn transgene exacer-
bated effects of Runx2 haploinsufficiency with a further reduction in calvarial
mineralization and near disappearance of clavicles. Notably, Runx2 +/−; Mek-
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FIGURE 6. Changes in RUNX2 phosphorylation and transcriptional activity in os-
teoblasts from TgMek-dn and TgMek-sp mice. (A, B) Regulation of RUNX2 phospho-
rylation. Calvarial cells were grown under differentiating conditions for 10 days before
metabolic labeling with [32P]-orthophosphate or [35S]-methionine/cysteine (to normalize
for total RUNX2) and immunoprecipitation with an anti-RUNX2 antibody. Each IP reaction
contained 500 g total protein. Normalized 32P incorporation into RUNX2 is shown in B.
(C, D) RUNX2-dependent transcriptional activity. Cells were transfected with p1.3mOG2-
luc (C) or p6OSE2mOG2-luc (D) plasmids and grown under differentiating conditions for
the times indicated before the measurement of luciferase activity. From Ge et al., 2007.27
sp embryos did not survive the birth process due to severe skeletal defects.
These experiments provide strong evidence that the ERK/MAPK pathway, via
actions on RUNX2 transcriptional activity, is important for normal osteoblast
differentiation and bone formation in vivo.
SUMMARY
Osteoblast differentiation is controlled by the sequential expression of sev-
eral transcription factors. Among these is RUNX2, which is associated with
commitment of mesenchymal cells to bone lineages and subsequent differ-
entiation of osteoblasts and hypertrophic chondrocytes. RUNX2 is expressed
throughout osteoblast and chondrogenic differentiation and appears to control
different events at different stages of cell maturation. Rather than being con-
trolled at transcriptional or translational levels, RUNX2 activity is controlled
by its interaction with accessory factors and by posttranslational modifications,
such as phosphorylation. Interaction of preosteoblasts with a type I collagen-
containing ECM stimulates differentiation by an integrin-mediated pathway
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FIGURE 7. Genetic interactions between Mek-dn and Mek-sp transgenes and Runx2.
TgMek-dn or TgMek-sp mice were crossed with Runx2+/− mice to generate the genotypes
indicated. (A–D) Partial rescue of CCD phenotype in Runx2+/− mice with Mek-sp. (A)
Skeletal whole mounts of newborn mice stained with alcian blue and alizarin red (top),
isolated clavicles (middle), and crania (bottom). (B–D) Measurements of femur length (B),
clavicle areas, (C) and mineralized area of calvaria (expressed as a fraction of total calvarial
area). (E–H) Increased severity of CCD phenotype with Mek-dn. Groups are as in panels
A–D. Statistical analysis values are expressed as means ± SD, n = 8/group. Comparisons
are indicated by bars. ∗ significantly different at P < 0.01. From Ge et al., 2007.27
that, via activation of ERK/MAP kinase, phosphorylates RUNX2 in the
C-terminal P/S/T domain to increase transcriptional activity. This regulation,
first identified in osteoblast cell cultures, also apparently occurs in vivo in that
transgenic modification of ERK/MAPK activity affects skeletal development
via a mechanism requiring RUNX2.
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